We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Merck Sets Aside $295 Million for Vioxx Defense; Reports Growth
Merck Sets Aside $295 Million for Vioxx Defense; Reports Growth
February 3, 2006
Merck has set aside $295 million in additional funds for litigation related to its withdrawn arthritis pain drug Vioxx, but is reporting a 2 percent increase in its fourth quarter profits thanks to strong sales of its asthma and cholesterol drugs.